Overview

A Study of Resveratrol as Treatment for Friedreich Ataxia

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of two doses of resveratrol taken for a 12 week period, on frataxin levels in individuals with Friedreich ataxia. This study will also measure the effect of resveratrol on markers of oxidative stress, clinical measures of ataxia, and cardiac parameters.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Murdoch Childrens Research Institute
Collaborator:
Friedreich's Ataxia Research Alliance
Treatments:
Resveratrol